Alzheimer clinical trial

IGC Pharma Inc (NYSE:IGC) witnessed a surge of 69.40%  in its stock value during after-hours trading on Wednesday. What Happened: The stock of IGC Pharma, a company involved in the development of cannabinoid-based therapies for Alzheimer‘s disease, rose by 69.40% to $0.62. This surge...

IGC Pharma Inc (AMEX:IGC) recently entered into a Master Cooperation Agreement with the University of Los Andes, focusing on integrating generative AI solutions into various aspects of drug development and clinical trials.  This collaboration aims to enhance the efficiency of clinical trials,...

India Globalization Capital, Inc. (AMEX: IGC) revealed the preliminary results of its exploratory endpoints from a Phase 1 clinical trial of a THC-drug to treat Alzheimer’s symptoms. The Phase 1 clinical trial provided valuable insights on Pharmacokinetics (PK) and genotyping...